New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Conventional vaccine adjuvants primarily rely on molecular binding and biochemical stimulation to activate immune responses, which often leads to limited efficacy in elderly or low-responsive ...
Researchers at the University of Southampton have developed a promising new way to bolster the body's immune system response ...
Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.
Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a ...
Are you feeling unmotivated to work out regularly during the COVID-19 pandemic? Do you need a fresh source of daily motivation to stick with an exercise regimen involving cardio and strength-training ...
– Proceeds will fund further development of AB248, a highly differentiated CD8-targeted IL-2 immunotherapy, through Phase 1b monotherapy expansion data, as well as initial safety and efficacy results ...
The parasite that may already live in your brain can infect the very immune cells trying to destroy it, but new UVA Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback